Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype

Neurobiology of Aging

Volumn 51, Issue , 2017, Pages 104-112

  Janelidze, Shorena ^a   Hertze, Joakim ^a,b   Nägga, Katarina ^a,b   Nilsson, Karin ^b   Nilsson, Christer ^a,b   Wennström, Malin ^c   van Westen, Danielle ^b,c   Blennow, Kaj ^d,e   Zetterberg, Henrik ^d,e,f   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid; APOE 4; Blood brain barrier; Dementia; Diabetes; Vascular pathology

Indexed keywords

ALBUMIN; AMYLOID PROTEIN; APOLIPOPROTEIN E; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ALBUMINOID; AMYLOID BETA PROTEIN; CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; SERUM ALBUMIN; VASCULOTROPIN A;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; BODY MASS; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMBRANE PERMEABILITY; MENTAL DISEASE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; WAIST HIP RATIO; X-RAY COMPUTED TOMOGRAPHY; BLOOD; CAPILLARY PERMEABILITY; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBUMINS; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL ADHESION MOLECULES; COHORT STUDIES; DEMENTIA; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; SERUM ALBUMIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85007609372     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.11.017     Document Type: Article

References (61)

1. Ambati, B.K., Nozaki, M., Singh, N., Takeda, A., Jani, P.D., Suthar, T., Albuquerque, R.J., Richter, E., Sakurai, E., Newcomb, M.T., Kleinman, M.E., Caldwell, R.B., Lin, Q., Ogura, Y., Orecchia, A., Samuelson, D.A., Agnew, D.W., St Leger, J., Green, W.R., Mahasreshti, P.J., Curiel, D.T., Kwan, D., Marsh, H., Ikeda, S., Leiper, L.J., Collinson, J.M., Bogdanovich, S., Khurana, T.S., Shibuya, M., Baldwin, M.E., Ferrara, N., Gerber, H.P., De Falco, S., Witta, J., Baffi, J.Z., Raisler, B.J., Ambati, J., Corneal avascularity is due to soluble VEGF receptor-1. Nature 443 (2006), 993–997.
2. American Psychiatric Association, Work Group to Revise DSM-III. Diagnostic and Statistical Manual of Mental Disorders: DSM-iii-r. third ed., 1987, American Psychiatric Association, Washington, DC.
3. Argaw, A.T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J.N., Mahase, S., Dutta, D.J., Seto, J., Kramer, E.G., Ferrara, N., Sofroniew, M.V., John, G.R., Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122 (2012), 2454–2468.
4. Bell, R.D., Winkler, E.A., Sagare, A.P., Singh, I., LaRue, B., Deane, R., Zlokovic, B.V., Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68 (2010), 409–427.
5. Bell, R.D., Winkler, E.A., Singh, I., Sagare, A.P., Deane, R., Wu, Z., Holtzman, D.M., Betsholtz, C., Armulik, A., Sallstrom, J., Berk, B.C., Zlokovic, B.V., Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485 (2012), 512–516.
6. Benaglia, T., Chauveau, D., Hunter, D.R., Young, D.S., Mixtools: an R Package for analyzing finite mixture models. J. Stat. Softw. 32 (2009), 1–29.
7. Berglund, G., Elmstahl, S., Janzon, L., Larsson, S.A., The Malmo diet and cancer study. Design and feasibility. J. Intern. Med. 233 (1993), 45–51.
8. Bien-Ly, N., Boswell, C.A., Jeet, S., Beach, T.G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., DeVoss, J., van der Brug, M., Watts, R.J., Lack of widespread BBB disruption in Alzheimer's disease models: focus on therapeutic antibodies. Neuron 88 (2015), 289–297.
9. Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6 (2010), 131–144.
10. Blennow, K., Wallin, A., Fredman, P., Karlsson, I., Gottfries, C.G., Svennerholm, L., Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol. Scand. 81 (1990), 323–326.
11. Blennow, K., Wallin, A., Uhlemann, C., Gottfries, C.G., White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol. Scand. 83 (1991), 187–193.
12. Bowman, G.L., Kaye, J.A., Moore, M., Waichunas, D., Carlson, N.E., Quinn, J.F., Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68 (2007), 1809–1814.
13. Bronge, L., Magnetic resonance imaging in dementia. A study of brain white matter changes. Acta Radiol. Suppl. 428 (2002), 1–32.
14. Brouns, R., Wauters, A., De Surgeloose, D., Marien, P., De Deyn, P.P., Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur. Neurol. 65 (2011), 23–31.
15. Burgmans, S., van de Haar, H.J., Verhey, F.R., Backes, W.H., Amyloid-beta interacts with blood-brain barrier function in dementia: a systematic review. J. Alzheimers Dis. 35 (2013), 859–873.
16. Chow, B.W., Gu, C., The molecular constituents of the blood-brain barrier. Trends Neurosci. 38 (2015), 598–608.
17. De Reuck, J., Deramecourt, V., Cordonnier, C., Auger, F., Durieux, N., Bordet, R., Maurage, C.A., Leys, D., Pasquier, F., Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: a 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. Eur. J. Neurol. 19 (2012), 1355–1360.
18. De Reuck, J., Deramecourt, V., Cordonnier, C., Leys, D., Pasquier, F., Maurage, C.A., Prevalence of cerebrovascular lesions in patients with Lewy body dementia: a neuropathological study. Clin. Neurol. Neurosurg. 115 (2013), 1094–1097.
19. Di Marco, L.Y., Venneri, A., Farkas, E., Evans, P.C., Marzo, A., Frangi, A.F., Vascular dysfunction in the pathogenesis of Alzheimer's disease—a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. 82 (2015), 593–606.
20. Erickson, M.A., Banks, W.A., Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 33 (2013), 1500–1513.
21. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975), 189–198.
22. Geser, F., Wenning, G.K., Poewe, W., McKeith, I., How to diagnose dementia with Lewy bodies: state of the art. Mov. Disord. 20:Suppl 12 (2005), S11–S20.
23. Halliday, M.R., Pomara, N., Sagare, A.P., Mack, W.J., Frangione, B., Zlokovic, B.V., Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol. 70 (2013), 1198–1200.
24. Hawkins, B.T., Lundeen, T.F., Norwood, K.M., Brooks, H.L., Egleton, R.D., Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50 (2007), 202–211.
25. Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C.H., Beach, T.G., Serrano, G.E., van Westen, D., Londos, E., Cenci, M.A., Hansson, O., Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 85 (2015), 1834–1842.
26. Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C.A., Baker, D., Blennow, K., Hansson, O., Plasma beta-amyloid in Alzheimer's disease and vascular disease. Sci. Rep., 6, 2016, 26801.
27. Karch, A., Manthey, H., Ponto, C., Hermann, P., Heinemann, U., Schmidt, C., Zerr, I., Investigating the association of ApoE genotypes with blood-brain barrier dysfunction measured by cerebrospinal fluid-serum albumin ratio in a cohort of patients with different types of dementia. PLoS One, 8, 2013, e84405.
28. Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10705–10709.
29. Llorens, F., Schmitz, M., Gloeckner, S.F., Kaerst, L., Hermann, P., Schmidt, C., Varges, D., Zerr, I., Increased albumin CSF/serum ratio in dementia with Lewy bodies. J. Neurol. Sci. 358 (2015), 398–403.
30. Lundqvist, R., Lilja, J., Thomas, B.A., Lotjonen, J., Villemagne, V.L., Rowe, C.C., Thurfjell, L., Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J. Nucl. Med. 54 (2013), 1472–1478.
31. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984), 939–944.
32. Meigs, J.B., Hu, F.B., Rifai, N., Manson, J.E., Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 (2004), 1978–1986.
33. Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., Toga, A.W., Jacobs, R.E., Liu, C.Y., Amezcua, L., Harrington, M.G., Chui, H.C., Law, M., Zlokovic, B.V., Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85 (2015), 296–302.
34. Nagga, K., Hansson, O., van Westen, D., Minthon, L., Wennstrom, M., Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia. J. Alzheimers Dis. 42 (2014), 1435–1441.
35. Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., Benson, D.F., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998), 1546–1554.
36. Nishitsuji, K., Hosono, T., Nakamura, T., Bu, G., Michikawa, M., Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J. Biol. Chem. 286 (2011), 17536–17542.
37. Olsson, B., Lautner, R., Andreasson, U., Ohrfelt, A., Portelius, E., Bjerke, M., Holtta, M., Rosen, C., Olsson, C., Strobel, G., Wu, E., Dakin, K., Petzold, M., Blennow, K., Zetterberg, H., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 15 (2016), 673–684.
38. Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D.J., Owenius, R., Hagerstrom, D., Wollmer, P., Minthon, L., Hansson, O., Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71 (2014), 1282–1289.
39. Petersen, R.C., Mild cognitive impairment as a diagnostic entity. J Intern Med 256 (2004), 183–194.
40. Qi, J.W., Qin, T.T., Xu, L.X., Zhang, K., Yang, G.L., Li, J., Xiao, H.Y., Zhang, Z.S., Li, L.Y., TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13863–13868.
41. Raz, L., Knoefel, J., Bhaskar, K., The neuropathology and cerebrovascular mechanisms of dementia. J. Cereb. Blood Flow Metab. 36 (2015), 172–186.
42. Reeson, P., Tennant, K.A., Gerrow, K., Wang, J., Weiser Novak, S., Thompson, K., Lockhart, K.L., Holmes, A., Nahirney, P.C., Brown, C.E., Delayed inhibition of VEGF signaling after stroke attenuates blood-brain barrier breakdown and improves functional recovery in a comorbidity-dependent manner. J. Neurosci. 35 (2015), 5128–5143.
43. Reiber, H., Flow rate of cerebrospinal fluid (CSF)—a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 122 (1994), 189–203.
44. Reiber, H., Peter, J.B., Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 184 (2001), 101–122.
45. Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., Amaducci, L., Orgogozo, J.M., Brun, A., Hofman, A., Moody, D.M., O'Brien, M.D., Yamaguchi, T., Grafman, J., Drayer, B.P., Bennett, D.A., Fisher, M., Ogata, J., Kokmen, E., Bermejo, F., Wolf, P.A., Gorelick, P.B., Bick, K.L., Pajeau, A.K., Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 (1993), 250–260.
46. Sjogren, M., Folkesson, S., Blennow, K., Tarkowski, E., Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J. Neurol. Neurosurg. Psychiatry 75 (2004), 1107–1111.
47. Skoog, I., Wallin, A., Fredman, P., Hesse, C., Aevarsson, O., Karlsson, I., Gottfries, C.G., Blennow, K., A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 50 (1998), 966–971.
48. Snyder, H.M., Corriveau, R.A., Craft, S., Faber, J.E., Greenberg, S.M., Knopman, D., Lamb, B.T., Montine, T.J., Nedergaard, M., Schaffer, C.B., Schneider, J.A., Wellington, C., Wilcock, D.M., Zipfel, G.J., Zlokovic, B., Bain, L.J., Bosetti, F., Galis, Z.S., Koroshetz, W., Carrillo, M.C., Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 11 (2015), 710–717.
49. Starr, J.M., Wardlaw, J., Ferguson, K., MacLullich, A., Deary, I.J., Marshall, I., Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 74 (2003), 70–76.
50. Suzuki, Y., Nagai, N., Yamakawa, K., Muranaka, Y., Hokamura, K., Umemura, K., Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice. J. Cereb. Blood Flow Metab. 35 (2015), 2021–2031.
51. Taheri, S., Gasparovic, C., Huisa, B.N., Adair, J.C., Edmonds, E., Prestopnik, J., Grossetete, M., Shah, N.J., Wills, J., Qualls, C., Rosenberg, G.A., Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 42 (2011), 2158–2163.
52. Tibbling, G., Link, H., Ohman, S., Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37 (1977), 385–390.
53. Tousoulis, D., Papageorgiou, N., Androulakis, E., Siasos, G., Latsios, G., Tentolouris, K., Stefanadis, C., Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J. Am. Coll. Cardiol. 62 (2013), 667–676.
54. van de Haar, H.J., Burgmans, S., Hofman, P.A., Verhey, F.R., Jansen, J.F., Backes, W.H., Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci. Biobehav Rev. 49 (2015), 71–81.
55. Wada, H., Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern. Med. 37 (1998), 509–513.
56. Wahlund, L.O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjogren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., Pasquier, F., Erkinjuntti, T., Scheltens, P., European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32 (2001), 1318–1322.
57. Wallin, A., Blennow, K., Fredman, P., Gottfries, C.G., Karlsson, I., Svennerholm, L., Blood brain barrier function in vascular dementia. Acta Neurol. Scand. 81 (1990), 318–322.
58. Winkler, E.A., Sengillo, J.D., Sagare, A.P., Zhao, Z., Ma, Q., Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J.S., Griffin, J.H., Cleveland, D.W., Zlokovic, B.V., Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E1035–E1042.
59. Zhang, Z.G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N., Chopp, M., VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 106 (2000), 829–838.
60. Zhao, Z., Nelson, A.R., Betsholtz, C., Zlokovic, B.V., Establishment and dysfunction of the blood-brain barrier. Cell 163 (2015), 1064–1078.
61. Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008), 178–201.